

Ref No: - Shukra/SEC/STOCK/2024-25 Date: 29/01/2025

To, Department of Corporate Services, BSE Limited, Phiroze Jeejeebhoy Towers Dalal Street, Fort, Mumbai - 400 001.

SECURITY CODE: 524632 || SECURITY ID: SHUKRAPHAR || ISIN: INE551C01028|| SERIES: EQ

SHUKR

PHARMACEUTICALS LTD

Dear Sir/Madam,

<u>Sub.: - Outcome of Board Meeting held today i.e. on January 29, 2025 pursuant to</u> <u>Regulation 30 of SEBI (Listing and Obligations and Disclosure Requirements)</u> <u>Regulations, 2015.</u>

Dear Sir/Madam,

In compliance with the provisions of Regulation 30 and other applicable provisions of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that Board of Directors of the Company at its meeting held today i.e. on January 29, 2025 has inter alia considered and approved the following:

1. Subject to the approval of the members and appropriate authorities, the Board has considered, approved and recommended for Sub-division of Company's 1 (One) Equity Share of Face Value of Rs. 10/- each into 10 (Ten) Equity Shares of Face Value of Re. 1/- each. The Record Date for Sub Division/ Stock Split shall be intimated in due course after taking approval of the Equity Shareholders of the Company.

The detailed disclosure as required under Regulation 30 of the Listing Regulations pursuant to SEBI circular No. SEBI/HO/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 read with SEBI Master Circular No: SEBI/HO/CFD/POD2/CIR/P/2023/120 dated 11th July, 2023 is enclosed as **Annexure-A**.

2. Pursuant to recommendation of Nomination and Remuneration Committee of the Company, and subject to approval of members of the Company, the Board has approved the regularization of appointment of Additional Independent Director Ms. Ritu Kapoor (DIN: 10334249), as an Independent Director of the Company.

The detailed disclosure as required under Regulation 30 of the Listing Regulations pursuant to SEBI circular No. SEBI/HO/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 read with SEBI Master Circular No: SEBI/HO/CFD/POD2/CIR/P/2023/120 dated 11th July, 2023 is attached as **Annexure-B**.

CIN : L24231GJ1993PLC019079



3. Pursuant to recommendation of Nomination and Remuneration Committee of the Company, and subject to approval of members of the Company, the Board has approved the regularization of Ms. Sheetal Shah (DIN: 00561649) as a Director of the Company.

HUKR

PHARMACEUTICALS LTD

The detailed disclosure as required under Regulation 30 of the Listing Regulations pursuant to SEBI circular No. SEBI/HO/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 read with SEBI Master Circular No: SEBI/HO/CFD/POD2/CIR/P/2023/120 dated 11th July, 2023 is attached as **Annexure-B**.

4. Pursuant to recommendation of Nomination and Remuneration Committee of the Company, and subject to approval of members of the Company, the Board has approved the appointment of Ms. Sheetal Shah (DIN: 00561649), as a Whole-time Director of the Company w.e.f. January 29, 2025:

The detailed disclosure as required under Regulation 30 of the Listing Regulations pursuant to SEBI circular No. SEBI/HO/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 read with SEBI Master Circular No: SEBI/HO/CFD/POD2/CIR/P/2023/120 dated July 11, 2023 is attached as Annexure-B.

5. Subject to approval of members of the Company, the Board has approved to alter the Memorandum of Association of the Company by deleting Clause III (C) i.e. other objects bearing clause no. 1 to 49.

The meeting of the Board of Directors commenced at 5:30 p.m. and concluded at 6.45.

You are therefore requested to take note of the same.

Thanking you,

Yours faithfully,

For, Shukra Pharmaceuticals Limited

Bhoomi Patel Director DIN: 08316893



CIN: L24231GJ1993PLC019079

Annexure-A

SHUKRA

PHARMACEUTICALS LTD.

DISCLOSURES PURSUANT TO REGULATION 30 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED 13TH JULY, 2023 READ WITH SEBI MASTER CIRCULAR NO: SEBI/HO/CFD/POD2/CIR/P/2023/120 DATED 11TH JULY, 2023

Sr. No	Particulars	Disclosure		
1	Split/ Sub-division Ratio	1 (One) Equity Share of Face Value of Rs. 10/-(Rupees Ten) each will be subdivided/ split into 10 (Ten) Equity Shares of Face Value of Rs. 1/- (Rupee One) each.		
2	Rationale behind the Split/ Sub-division	 To enhance the liquidity in the capital market; To widen the shareholder base and To make the shares affordable/ accessible to small/ retail in the Stock Market 		
3	Pre and Post Share Capital- authorized, paid-up and subscribed	Share Capital	Pre-Split	
			No. of Shares	Amount
		Authorized Share Capital	4,90,00,000 (Four Crore Ninety Lacs) Equity Shares of Rs.10/- (Rupees Ten) each	Rs. 49,00,00,000/-
		Subscribed and Paid- up Share Capital	4,37,87,944 (Four Crore Thiry Seven Lacs Eighty-Seven Thousand Nine Hundred and Forty-Four) Equity Shares of Rs.10/- (Rupees Ten) each	Rs. 43,78,79,440/-
		Share Capital	Post-Split	
		Sapital	No. of Shares	Amount
		Authorized Share Capital	49,00,00,000 (Forty-Nine Crores) Equity Shares of Rs.1/- (Rupees One) each	Rs. 49,00,00,000/-

SUB-DIVISION OF EQUITY SHARES

CIN: L24231GJ1993PLC019079





		Subscribed43,78,79,440(Forty- Rs.and Paid- up ShareThree Crore Seventy- Eight Lakhs Seventy-Nine Thousand Four Hundred and Forty) Equity Shares of Rs.1/- (Rupees One) each43,78,79,440/-		
4	Expected time of completion	Within 3 months from the approval of the Board of Directors.		
5	Class of shares which are consolidated or subdivided	Equity Shares		
6	Number of shares of each class pre and post- split or consolidation	Already Mentioned in Point No (3)		
7	Number of shareholders who did not get any shares in consolidation and their pre-consolidation shareholding	Not Applicable		

DISCLOSURES PURSUANT TO REGULATION 30 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, PURSUANT TO SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD1/P/CIR/2023/123 DATED 13TH JULY 2023 READ WITH SEBI MASTER CIRCULAR NO. SEBI/HO/CFD/POD2/CIR/P/2023/120 DATED 11TH JULY, 2023

ALTERATION OF CAPITAL CLAUSE

"The Aut<mark>horised Share Capital</mark> of the Company is Rs. 49,00,00,000 (Rupees Forty-Nine Crores Only) divided into 43,78,79,440 (Forty-Three Crore Seventy-Eight Lakhs Seventy-Nine Thousand Four Hundred and Forty Only) Equity Shares of Re.1/- (Rupee One) each."

CIN : L24231GJ1993PLC019079

Annexure-B

SHUKRA

PHARMACEUTICALS LTD.

DISCLOSURES PURSUANT TO REGULATION 30 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, PURSUANT TO SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD1/P/CIR/2023/123 DATED 13TH JULY 2023 READ WITH SEBI MASTER CIRCULAR NO. SEBI/HO/CFD/POD2/CIR/P/2023/120 DATED 11TH JULY, 2023.

Sr. No.	Particulars	Information		
1	Name of Director	Ritu Kapoor	Sheetal Shah	
2	Reason for change viz. appointment, resignation removal, death or otherwise	Ms. Ritu Kapoor appointed as an Independent Director on the Board of the Company for a period of five years w.e.f. October 25, 2024, subject to the approval of members of the Company.	appointed as a Whole-time Director on the Board of the Company w.e.f. January 29, 2025, subject to the approval of	
3	Date of appointment / re-appointment / cessation (as applicable) & term of appointment / re- appointment	October 25, 2024 Five years w.e.f. October 25, 2024	January 29, 2025 Three years w.e.f. January 29, 2025	
4	Brief Profile (in case of appointment)	She has huge experience of administration for more than 25 years and also good at conversation with legal and compliance matters.	More than 30 years of experience in the field of Human Resources and General Administration work	
5	Disclosure of relationships between directors (in case of Appointment of a director)	Nil	Ms. Sheetal Shah is wife of Mr. Dakshesh Rameshchandra Shah Managing Director of the Company. And Mother of Mr. Dhruvin Shah, Whole time Director of the Company.	

CIN: L24231GJ1993PLC019079